Physician profile
Albert K Holmes
NPI 1720060676
$947.81
in general payments reported to CMS, 2019-2025
12 companies · $88.33 in 2025
The $88.33 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $111 · 2021: $61.86 · 2023: $168 · 2025: $88.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $256.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $327.84 | 2019 | |
| Genentech, INC. | $168.25 | 2023-2025 | Susvimo, Vabysmo |
| Regeneron Pharmaceuticals, INC. | $149.64 | 2021-2023 | Eylea |
| Novartis Pharmaceuticals Corporation | $93.86 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $46.62 | 2019-2020 | |
| Genentech USA, INC. | $31.11 | 2019 | |
| Ivantis, INC | $30.24 | 2020 | |
| Horizon Therapeutics Plc | $28.23 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $23.05 | 2019 | |
| Biotissue Holdings INC. | $18.02 | 2020 | |
| Shire North American Group INC | $16.00 | 2019 | |
| Aerie Pharmaceuticals, INC. | $14.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.